Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
-1.74%
)
US TECH 100
23,040.00
(
-2.01%
)
Dow Jones
45,960.11
(
-1.01%
)
Brent Oil
100.96
(
0.28%
)
Bitcoin
68,819.62
(
0.05%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 2752

Wednesday, 10/06/2004 5:58:17 PM

Wednesday, October 06, 2004 5:58:17 PM

Post# of 257295
Lucentis update from DNA CC:

The U.S. phase-3 trial in predominantly-classic AMD finally completed enrollment during Q3. Please see #msg-3507775 for the prior guidance.

Data from the other U.S. phase-3 Lucentis trial –the one in minimally-classic/occult AMD— will be released during 2Q05.

NVS is conducting its own clinical trials of Lucentis in Europe.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today